CoronaryAtlas logo
CoronaryAtlas
cyclooxygenase
Pathway / Thromboxane amplification

cyclooxygenase

protein

Cyclooxygenase-1 catalyzes arachidonic acid conversion to thromboxane-A2, driving platelet recruitment and coronary thrombosis.

Pathway placement
Cascade stepThromboxane amplification
Confidencehigh
RationaleCOX-1 catalyzes thromboxane-A2 synthesis; aspirin target; central to platelet amplification.
Also acts inVascular inflammation
Druggability
Not assessed (no mapped human gene target).

Type I vs non-Type I discrimination

ScoresShared / rises in both
R — rupture / Type-I
67
C — non-Type-I
58
A — assay feasibility
68
E — evidence strength
42
T1DI (composite)
16
Specificity differential (R−C)+8.4
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationmag 2
2anemia / acute blood lossn/a
2hypovolemia / dehydrationmag 2
2tachyarrhythmiamag 2
2hypoxemia / respiratory failuremag 1
2hypertensive emergencymag 1
2high-demand / peri-operative stressmag 2
3sudden cardiac deathn/a
4aPCI-related periproceduraln/a
4bstent thrombosisn/a
4cin-stent restenosismag 2
5CABG-relatedmag 2
Coverage: 8/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 20 supporting references. See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)

Literature evidence(2)

Clinical trials(1)